Suppr超能文献

脊髓灰质炎流行病学:新冠疫情后根除脊髓灰质炎的策略与挑战

Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.

作者信息

Bricks Lucia F, Macina Denis, Vargas-Zambrano Juan C

机构信息

Sanofi Vaccines Medical, Av Nações Unidas, São Paulo 14401, Brazil.

Sanofi Vaccines Medical, 14 Espace Henri Vallee, 69007 Lyon, France.

出版信息

Vaccines (Basel). 2024 Nov 26;12(12):1323. doi: 10.3390/vaccines12121323.

Abstract

The Global Polio Eradication Initiative (GPEI), launched in 1988, has successfully reduced wild poliovirus (WPV) cases by over 99.9%, with WPV type 2 and WPV3 declared eradicated in 2015 and 2019, respectively. However, as of 2024, WPV1 remains endemic in Afghanistan and Pakistan. Since 2000, outbreaks of circulating virus derived of polio vaccines (cVDPVs) have emerged in multiple regions, primary driven by low vaccine coverage rates (VCRs). The COVID-19 pandemic disrupted routine immunization, resulting in millions of unvaccinated children, and leaving many countries vulnerable to both WPV1 and cVDPVs outbreaks. This paper reviews the epidemiological landscape of poliomyelitis post the COVID-19 pandemic, and the strategies and challenges to achieve the global polio eradication.

摘要

全球根除脊髓灰质炎行动(GPEI)于1988年启动,已成功将野生脊髓灰质炎病毒(WPV)病例减少了99.9%以上,2型和3型野生脊髓灰质炎病毒分别于2015年和2019年宣布根除。然而,截至2024年,1型野生脊髓灰质炎病毒在阿富汗和巴基斯坦仍然流行。自2000年以来,多个地区出现了由脊髓灰质炎疫苗衍生的循环病毒(cVDPV)疫情,主要原因是疫苗接种覆盖率(VCR)较低。COVID-19大流行扰乱了常规免疫,导致数百万儿童未接种疫苗,使许多国家容易受到1型野生脊髓灰质炎病毒和cVDPV疫情的影响。本文回顾了COVID-19大流行后脊髓灰质炎的流行病学情况,以及实现全球根除脊髓灰质炎的策略和挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1681/11680066/72dc75666c24/vaccines-12-01323-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验